Boretti Alberto
Independent Scientist, Johnsonville Road, Johnsonville, Wellington 6037, New Zealand.
Nat Prod Commun. 2022 Mar 8;17(3):1934578X221080929. doi: 10.1177/1934578X221080929. eCollection 2022 Mar.
SARS-CoV-2 spike protein-induced heart inflammation may originate from either COVID-19 infection or the administration of COVID-19 mRNA vaccines. As pyrroloquinoline quinone (PQQ) is a scavenger of free radicals, redox cofactor, and antioxidant which supports cognitive and mitochondrial functions, supplementation with PQQ could have a positive effect to reduce heart inflammation after COVID-19 mRNA vaccines. However, there is no evidence yet for this opportunity in the literature. Cellular and animal model results are missing. Similarly, no clinical trials have been conducted. While it is recommended to measure the levels of the cardiac biomarkers before and after COVID-19 vaccination, no recommendation can be made about supplementation with PQQ, which, however, we note has no contraindication.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白引发的心脏炎症可能源于新型冠状病毒肺炎（COVID-19）感染或COVID-19 mRNA疫苗的接种。由于吡咯喹啉醌（PQQ）是一种自由基清除剂、氧化还原辅助因子和抗氧化剂，可支持认知和线粒体功能，补充PQQ可能对减轻COVID-19 mRNA疫苗接种后的心脏炎症产生积极作用。然而，文献中尚无关于这一可能性的证据。缺乏细胞和动物模型的研究结果。同样，也未进行临床试验。虽然建议在接种COVID-19疫苗前后测量心脏生物标志物水平，但对于补充PQQ尚无推荐意见，不过我们注意到PQQ没有禁忌证。
